Nasus Pharma Ltd
NSRX7.260USD
+0.890+13.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
65.77MMarket Cap
LossP/E TTM
More Details of Nasus Pharma Ltd Company
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
Nasus Pharma Ltd Info
Ticker SymbolNSRX
Company nameNasus Pharma Ltd
IPO dateAug 13, 2025
CEOTeleman (Dan)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 13
AddressYigal Alon 65
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryIsrael
Postal code- -
Phone97237326616
Websitehttps://www.nasuspharma.com
Ticker SymbolNSRX
IPO dateAug 13, 2025
CEOTeleman (Dan)
Company Executives of Nasus Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+3.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+2.32%
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Other
36.92%
Shareholders
Shareholders
Proportion
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Other
36.92%
Shareholder Types
Shareholders
Proportion
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.04%
Other
34.98%
Institutional Shareholding
Updated: Fri, Sep 12
Updated: Fri, Sep 12
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
7
5.35M
59.33%
+5.35M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilboa (Udi)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Megiddo (Dalia)
1.85M
20.48%
+1.85M
--
Aug 12, 2025
Hershman Holdings L.L.C.
477.01K
5.29%
+477.01K
--
Aug 12, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
+429.31K
--
Aug 12, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Nasus Pharma Ltd?
The top five shareholders of Nasus Pharma Ltd are:
Gilboa (Udi) holds 1.85M shares, accounting for 20.48% of the total shares.
Megiddo (Dalia) holds 1.85M shares, accounting for 20.48% of the total shares.
Hershman Holdings L.L.C. holds 477.01K shares, accounting for 5.29% of the total shares.
Capital Point Ltd holds 575.13K shares, accounting for 6.38% of the total shares.
Phoenix Solutions Ltd holds 429.31K shares, accounting for 4.76% of the total shares.
Gilboa (Udi) holds 1.85M shares, accounting for 20.48% of the total shares.
Megiddo (Dalia) holds 1.85M shares, accounting for 20.48% of the total shares.
Hershman Holdings L.L.C. holds 477.01K shares, accounting for 5.29% of the total shares.
Capital Point Ltd holds 575.13K shares, accounting for 6.38% of the total shares.
Phoenix Solutions Ltd holds 429.31K shares, accounting for 4.76% of the total shares.
What are the top three shareholder types of Nasus Pharma Ltd?
The top three shareholder types of Nasus Pharma Ltd are:
Gilboa (Udi)
Megiddo (Dalia)
Hershman Holdings L.L.C.
Gilboa (Udi)
Megiddo (Dalia)
Hershman Holdings L.L.C.
How many institutions hold shares of Nasus Pharma Ltd (NSRX)?
As of 2025Q3, 7 institutions hold shares of Nasus Pharma Ltd, with a combined market value of approximately 5.35M, accounting for 59.33% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for Nasus Pharma Ltd?
In --, the -- business generated the highest revenue for Nasus Pharma Ltd, amounting to -- and accounting for --% of total revenue.
